D.E. Shaw & Co
BPMC

D.E. Shaw & Co’s Blueprint Medicines BPMC Stock Holding History

D.E. Shaw & Co’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39,100
Closed -$5.01M – 4576
2025
Q2 		$5.01M Hold
39,100
– – ﹤0.01% 2032
2025
Q1 		$3.46M Hold
39,100
– – ﹤0.01% 2172
2024
Q4 		$3.41M Hold
39,100
– – ﹤0.01% 2294
2024
Q3 		$3.62M Buy
39,100
+29,100
+291% +$2.89M ﹤0.01% 2214
2024
Q2 		$1.08M Buy
+10,000
New +$1M ﹤0.01% 3152

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

D.E. Shaw & Co's BPMC Position: Q2 2025 in Review

D.E. Shaw & Co sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 388,986 shares — an estimated $40.4M sold.

D.E. Shaw & Co first reported a position in BPMC in Q2 2015 and held it in 28 quarters. The position peaked at $35.7M in Q1 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • D.E. Shaw & Co reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 388,986 Blueprint Medicines shares in Q2 2025, an estimated $40.4M.
  • D.E. Shaw & Co first reported a position in Blueprint Medicines in Q2 2015 and held it in 28 quarters.
  • D.E. Shaw & Co's Blueprint Medicines position peaked at $35.7M in Q1 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.